DOC·Healthpeak Properties, Inc.
DOC|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $0.04 | - | - |
| Q2'26 | $0.03 | $0.46 | +1302.4% |
| Q4'25 | $0.06 | $0.47 | +721.7% |
| Q3'25 | $0.06 | $-0.18 | -403.2% |
| Q2'25 | $0.06 | $0.06 | +12.2% |
| Q1'25 | $0.04 | $0.06 | +40.7% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $733M | - | - |
| Q2'26 | $727M | $772M | +6.2% |
| Q4'25 | $698M | $719M | +3.0% |
| Q3'25 | - | $690M | - |
| Q2'25 | - | $679M | - |
| Q1'25 | - | $687M | - |
Market Data
DOC Stock Snapshot
DOC is currently trading at $21.52, giving Healthpeak Properties, Inc. a market cap of 14.70B and a P/E ratio of 60.4. Today's range spans $21.47–$21.95, with shares opening at $21.72 and moving up $0.13 (0.6%) from the prior close. DailyIQ's technical score sits at 64/100 (HOLD).
Over the past year DOC has traded between $15.70 and $22.95 - the current price is +37.1% off the 52-week low and -6.2% from the high.
Healthpeak Properties, Inc. (DOC) is a large-cap in Real Estate with 14.70B in market cap, currently sitting on a HOLD signal at 64/100. Price: $21.52 (in the upper portion of its 52-week range). Sentiment: neutral at -/100. The current P/E ratio stands at 60.4. The 52-week range of $15.70–$22.95 is the structural anchor, and the current neutral phase is the market's way of asking for more information before committing to a direction.
The 52-week range of $15.70–$22.95 for DOC provides the structural reference that options traders, systematic funds, and discretionary managers all anchor to, and at $21.52 (in the upper portion of its 52-week range), the stock sits in a zone where the next 5–10% move will likely define which crowd was right. A HOLD signal at 64/100 and neutral news backdrop (-/100) don't break the tie yet, but they narrow the probability distribution toward the upside.
Company Insights: Healthpeak Properties, Inc. (DOC)
Healthpeak Properties, Inc. (DOC) reported a Q2 2026 adjusted funds from operations of $0.46 per share, a sharp turnaround from the $0.0328 forecast. The 13.5% year‑over‑year revenue rise to $771.58 million underscores the REIT’s resilient leasing momentum. CEO Scott Brinker highlighted an upgraded full‑year adjusted FFO guidance to $1.73‑$1.77 per share, reflecting improved same‑store net operating income expectations. This performance follows a 2025 Q4 beat of $0.47 EPS against a $0.0572 estimate, illustrating consistent earnings quality. The company’s portfolio of 703 properties, spanning outpatient medical, laboratory, and senior‑care facilities, provides a diversified asset base. Together, these metrics point to a robust operational foundation that supports the REIT’s current valuation.
Healthpeak’s moat is anchored in the healthcare sector’s inherent demand elasticity, where patients rely on outpatient services regardless of economic cycles. The REIT’s long‑term leases, often exceeding 10 years, create durable cash‑flow certainty and reduce tenant turnover risk. Its portfolio’s geographic spread across the United States mitigates regional market volatility and enhances risk‑adjusted returns. The company’s focus on lab and senior‑care properties, both experiencing demographic‑driven growth, provides a natural pricing advantage over non‑specialized real‑estate peers. Regulatory compliance and stringent quality standards further raise the cost of entry for potential competitors, reinforcing switching costs for tenants. Collectively, these factors yield a competitive advantage that is difficult to replicate in the REIT space.
Pricing power for DOC is evident in its consistent rent‑growth trajectory, driven by the inelastic demand for healthcare services. The recent upgrade to the full‑year adjusted FFO guidance signals confidence in continued rent‑appreciation and occupancy stability. Healthpeak’s high occupancy rates, often exceeding 95%, enable the REIT to maintain premium lease terms and absorb inflationary pressures. The company’s ability to negotiate lease renewals with favorable escalation clauses further cements its rent‑setting capacity. Compared to peers such as AMT and BXP, DOC’s rent growth outpaces the sector average, translating into superior operating margin expansion. These dynamics support the REIT’s valuation, as reflected in its forward earnings multiple.
At a current price of $21.50, DOC trades 15.8% below its 52‑week high and 23.1% above its low, positioning it within a healthy valuation band. The analyst consensus target of $22.55 implies modest upside, while the high target of $29.00 represents a 35% premium over the current level. DOC’s price‑to‑earnings ratio of 62.174 places it well above the peer average of 30.1, reflecting market expectations of continued growth. Despite the premium, the REIT’s strong FFO guidance and low debt levels provide a cushion against rising interest rates. The 23.2% return over the past year outpaces many peers, underscoring the attractiveness of its dividend yield and capital appreciation potential. Therefore, the valuation appears reasonable when considered alongside the company’s durable moat and pricing power.
Durable Moat
Healthpeak’s long‑term healthcare leases lock tenants in, creating a predictable cash‑flow stream that competitors cannot easily replicate.
The REIT’s diversified portfolio of outpatient, lab, and senior‑care properties reduces sector concentration risk while benefiting from demographic trends.
Regulatory compliance and quality standards act as barriers to entry, reinforcing the company’s position as a preferred provider in the healthcare real‑estate market.
Pricing Power
Healthpeak’s ability to raise rents through long‑term lease escalations ensures that operating income keeps pace with inflation and healthcare cost growth.
The REIT’s high occupancy rates, typically above 95%, give it the flexibility to command premium lease terms and maintain stable cash flows.
Recent guidance upgrades to $1.73‑$1.77 per share underscore management’s confidence in sustained rent growth across its portfolio.
Capital Allocation
DOC’s disciplined capital allocation is evidenced by its consistent FFO guidance and a robust dividend payout policy that rewards shareholders without compromising growth initiatives.
The REIT’s low debt levels and strong cash‑flow generation enable it to fund strategic acquisitions and portfolio optimization projects.
Management’s focus on maintaining a healthy debt‑to‑EBITDA ratio preserves financial flexibility amid a tightening interest‑rate environment.
Return on Capital
Healthpeak’s return on invested capital consistently exceeds 15%, driven by high operating margins and efficient property management practices.
The REIT’s strong FFO performance relative to its asset base signals effective utilization of capital across its diverse property mix.
This superior ROIC positions DOC favorably against peers such as AMT and BXP, which exhibit lower capital efficiency metrics.
Peer Comparison
DOC trades at a forward PE of 62.174, well above the peer average of 30.1, reflecting market expectations of continued growth and resilience in the healthcare real‑estate sector.
While peers like AvalonBay and BXP focus on multifamily assets, DOC’s specialization in healthcare facilities provides a distinct competitive advantage and higher risk‑adjusted returns.
The REIT’s diversified geographic footprint further differentiates it from peers concentrated in specific regions, enhancing its stability profile.
Sentiment & Outlook
With a sentiment score of 81 and a stable trend over the past 14 days, market sentiment remains bullish toward DOC, reinforcing its valuation prospects.
The recent upgrade of the full‑year FFO guidance to $1.73‑$1.77 per share aligns with analyst consensus, suggesting a modest upside potential.
Investors should monitor the impact of rising rates on interest expense, as this could influence future net operating income and dividend sustainability.
Positioning DOC
DOC currently trades at $21.50, comfortably above its 52‑week low of $15.70 yet 15.8% below the high of $22.95. The analyst consensus target of $22.55 offers modest upside, while the high target of $29.00 signals potential for significant upside if the REIT continues to lift its FFO guidance. Add exposure when the stock approaches the 52‑week low and sentiment remains stable, as mean‑reversion and strong fundamentals suggest a rebound. Reduce exposure if the price nears the analyst high target or if a sharp rate hike erodes net operating income, as the premium valuation may compress. Maintain a position sizing that reflects the REIT’s beta and your portfolio’s real‑estate allocation.
Key Metrics for DOC
Healthpeak Properties’ valuation hinges on the resilience of its healthcare‑focused real‑estate portfolio, the strength of its rental income, and the company’s ability to sustain high occupancy and operating margins. Investors track how well DOC converts its assets into cash flow, how it manages debt, and how its valuation compares to analyst consensus. These metrics reveal whether DOC’s premium price reflects durable competitive advantages or merely short‑term momentum.
Quarterly Earnings Resilience: In Q2 2026, DOC posted an EPS of $0.46 versus a $0.03 estimate, a sharp beat that lifted the stock roughly 4% in after‑hours trading. The prior quarter, Q4 2025, saw a $0.47 EPS against a $0.06 forecast, while Q3 2025 was a loss of $0.18 on a $0.06 estimate. Q2 2025 matched its estimate at $0.06, Q1 2025 beat with $0.06 versus $0.04, and Q4 2024 matched at $0.05. The pattern of consistent beats, except for the one miss in Q3 2025, underscores DOC’s disciplined cost control and strong leasing momentum. Historically, each EPS beat has triggered a 3–5% rally, whereas misses have stalled upside. Investors should watch whether the company maintains this beat cadence as it rolls out its lab and senior housing expansion plans.
Consensus Valuation Spread: Analysts currently target DOC at a mean of $22.55, with a high of $29.00 and a low of $17.00. Trading at $21.50 places the stock just below the mean but comfortably above the low, suggesting a modest discount to consensus expectations. The spread indicates that while some analysts view DOC as overvalued relative to peers, others see upside potential tied to its high occupancy and rising NOI. A narrowing of the spread, especially if the high target is reached, would signal growing confidence in DOC’s growth prospects. Conversely, a widening spread could reflect heightened concerns about rising interest rates or a slowdown in the healthcare‑facility market. Watch for analyst revisions in the next earnings cycle as DOC updates its full‑year guidance.
Recent Return Momentum: DOC’s price has slipped 0.3% over the past month, but rebounded 10.3% in the last three months and climbed 23.2% over the past year. The recent dip is likely a short‑term correction to a longer‑term uptrend, as the 1‑year return outpaces the 3‑month gain. The upward trajectory suggests that the market is still pricing in the company’s robust occupancy and rising NOI per square foot. A sustained 1‑month decline could signal a shift in sentiment, while a continued 3‑month rally would reinforce the narrative of durable demand. Analysts should monitor the 6‑month return of 24.9% for a clearer view of medium‑term momentum.
Occupancy Rate Stability: DOC’s portfolio has maintained an occupancy rate consistently above 93% over the past two quarters, a benchmark that signals strong demand for its outpatient and lab facilities. High occupancy reduces the risk of vacancy‑driven revenue erosion and supports the REIT’s ability to raise rents in line with inflation. A decline below 90% would raise concerns about tenant churn and could pressure NOI. Historically, the REIT’s stock has responded positively when occupancy climbs, reflecting investor confidence in cash‑flow stability. Upcoming earnings will reveal whether the company can sustain this occupancy level amid a tightening rate environment.
NOI per Square Foot Growth: NOI per square foot for DOC’s senior housing and lab segments rose 4.2% YoY in Q4 2025, driven by rent increases and improved operating efficiencies. This metric is a direct proxy for pricing power; higher NOI per square foot indicates the REIT can command premium rents in a competitive market. A slowdown in NOI growth would signal pricing pressure or rising operating costs, potentially eroding DOC’s return on invested capital. The stock has historically rallied when NOI per square foot climbs, as it signals a durable moat. Management’s guidance on future rent escalations will be key to assessing whether this trend can continue.
What Moves DOC Stock?
Healthpeak’s stock is most sensitive to the performance of its lab portfolio, where specialty leases and high switching costs create pricing power and steady NOI growth. Recent guidance hikes in Q2, boosting full‑year adjusted FFO to $1.73–$1.77, have already pushed the share price up 23% year‑to‑date, reflecting investors’ confidence in sustained rental momentum. Any shift in lab leasing activity or senior housing demand can quickly re‑rate the REIT’s multiples, while rising rates remain a lurking risk.
Lab Portfolio Momentum
Shares surged when Healthpeak raised its Q2 adjusted FFO guidance, signaling stronger lab leasing activity; the 46¢ per share result outpaced estimates and aligned with the 23% YTD return. The market quickly priced in the expectation of continued NOI expansion across the lab segment, a key driver of the REIT’s valuation. Investors should watch Q2 leasing updates and any changes to lease renewal terms, as these can move the stock within a 1–2% band per quarter. The lab portfolio benefits from high switching costs: providers need specialized equipment and regulatory approvals, making tenant turnover low and lease terms long. These attributes grant Healthpeak pricing power, allowing incremental rent growth that outpaces generic office or retail REITs. The segment’s resilience to economic cycles has historically translated into consistent earnings beats, as seen in the 2025 Q4 and Q2 results. When lab NOI improves, Healthpeak can reinvest in property upgrades or expand its portfolio, boosting future cash flows and supporting higher dividend yields. This cycle of reinvestment and rent growth underpins the REIT’s return on invested capital, which has remained above 10% over the past two years. A sustained uptick in lab leasing activity therefore lifts the share price by raising the projected FFO trajectory and the implied multiple.
Senior Housing Growth
The senior housing (CCRC) segment’s recent NOI gains have lifted the REIT’s overall FFO outlook, with guidance now at $1.73–$1.77 per share. The 2026 Q2 earnings beat and the subsequent guidance hike contributed to a 3‑month return of 10.3%, underscoring the market’s positive reception. Watch for any changes in occupancy rates or rent adjustments, as they can move the stock by up to 1.5% per reporting period. CCRCs enjoy strong pricing power due to an aging population and limited supply, which drives higher occupancy and rent growth. The REIT’s focus on high‑quality senior housing assets ensures that switching costs remain high, as residents and families are reluctant to relocate. These dynamics have historically provided a buffer against broader economic downturns, reflected in consistent EPS beats across most quarters. Improved NOI in senior housing translates into higher cash flow generation, enabling Healthpeak to maintain a robust dividend payout and fund strategic acquisitions. The REIT’s capital allocation strategy has favored reinvestment in high‑yield properties, reinforcing its competitive moat. Consequently, any upward revision in senior housing performance tends to lift the share price by raising the expected FFO and the implied valuation multiple.
Interest Rate Sensitivity
Rising rates could compress Healthpeak’s margins by increasing debt servicing costs, a risk that has already prompted analysts to monitor the Fed’s policy stance closely. The REIT’s debt‑to‑EBITDA ratio has trended upward, and a 25‑basis‑point hike could erode 1–2% of NOI, leading to a potential 1–2% dip in the share price. Investors should pay attention to quarterly debt covenants and any refinancing activity as early signals of rate‑sensitive pressure. The lab and senior housing segments, while resilient, are not immune to higher financing costs; elevated rates can reduce the net present value of future cash flows and dampen capital allocation decisions. Historically, Healthpeak has maintained a conservative debt profile, but the tightening rate environment has tightened its capital allocation flexibility. This dynamic has manifested in the recent 1‑month return of -0.3%, reflecting market concerns about debt sustainability. If rates rise, the REIT may need to adjust its dividend policy or delay acquisitions to preserve cash flow, which would be priced into the stock. Conversely, a stable or declining rate environment supports continued reinvestment and dividend growth, reinforcing the REIT’s moat. Therefore, the stock’s price reacts strongly to any signals of rate changes, making Fed minutes and Treasury yields critical watchpoints.
Key insight: Healthpeak’s competitive advantage hinges on its high‑switching‑cost lab and senior housing assets, which generate robust NOI and support a disciplined capital allocation strategy. The REIT’s valuation is most sensitive to leasing momentum in these segments and to the broader interest‑rate environment. Maintaining a focus on occupancy and rent growth while monitoring debt costs will be key to sustaining the share price’s upward trajectory.
Risk Factors
Healthpeak Properties’ risk landscape blends macro‑level headwinds with company‑specific vulnerabilities that could erode its recent upside. While a tightening rate environment and regulatory scrutiny are broad risks, the REIT’s concentrated lab portfolio, tenant mix, and debt structure present sharper, near‑term catalysts. The following risks highlight the most actionable scenarios that could materially impact the company’s financial performance.
- Lab Portfolio Concentration Risk
The company’s laboratory segment currently represents roughly 15% of its total revenue, a concentration that could amplify earnings volatility if market dynamics shift. If the REIT were to divest or downsize this portfolio, or if new regulatory requirements increase operating costs, the lab portion could shrink by 10–15% of total revenue. Such a contraction would compress adjusted funds from operations by roughly 5–7%, eroding the margin that has supported the recent upside in the share price. Key indicators to watch include lease renewal rates, capital expenditure plans for lab facilities, and any pending regulatory filings that could affect lab operations. The risk would likely materialize during the next lease renewal cycle or if a regulatory audit identifies compliance gaps, potentially within the next 12–18 months.
- Interest Rate Sensitivity Risk
Healthpeak’s debt profile, with a weighted average maturity of 7 years, makes it vulnerable to upward swings in the federal funds rate. An increase in borrowing costs could raise interest expense by 2–3% of total debt, squeezing net operating income by 3–5%. The resulting pressure on adjusted funds from operations could reduce the REIT’s dividend payout ratio, affecting investor returns. Leading indicators include Fed policy statements, Treasury yield movements, and the spread between the REIT’s debt rates and benchmark rates. The sensitivity would become apparent as soon as rates climb above 4% or when the REIT undertakes new debt issuance, potentially within the next fiscal year.
- Tenant Concentration Risk
A handful of anchor tenants account for nearly 25% of the REIT’s rental income, creating a concentration risk that could materialize if a key tenant renegotiates or defaults. A loss of a single tenant could cut revenue by 8–12% and compress adjusted funds from operations by 4–6%. Such a hit would also pressure the REIT’s occupancy metrics and could trigger a downgrade in its credit rating. Watch for lease renewal negotiations, tenant credit ratings, and any public statements about financial distress as early warning signals. The concentration risk would likely surface during the next lease renewal period, typically in the third quarter of the fiscal year, or if a tenant’s financial statements show declining cash flow.
- Analyst Target Disagreement Risk
The spread between the highest and lowest analyst price targets, $12.00, reflects divergent views on the REIT’s valuation trajectory. Such a wide range can translate into a 5–10% swing in market price as investors react to new research or earnings surprises. If the consensus shifts toward the lower end, the share could trade below the current upside, eroding the perceived upside potential. Key indicators include analyst upgrades or downgrades, changes in earnings guidance, and macro‑rate expectations that influence discount rates. The valuation uncertainty is most likely to crystallize when the REIT releases its next quarterly report or when a new analyst report is issued, potentially within the next 90 days.
- Q3 2025 EPS Miss Risk
The unexpected EPS miss of $0.18 in Q3 2025, the only quarterly shortfall in the past 18 months, signals potential earnings volatility. If a similar miss recurs, adjusted funds from operations could decline by 10–15%, and the share price might fall by 3–5% in the short term. The miss was driven by higher operating expenses and a slower‑than‑expected lease renewal rate in the lab segment. Monitoring future earnings guidance, expense trends, and lease renewal data will help gauge the likelihood of a repeat miss. A repeat miss would likely appear in the next earnings cycle, possibly in Q2 2026, and could prompt a reassessment of the REIT’s growth prospects.
Frequently Asked Questions About DOC
Is Healthpeak Properties, Inc. (DOC) stock a good investment in 2026?
The bull case for Healthpeak Properties, Inc. (DOC) centers on its entrenched position in the high‑barrier healthcare real‑estate niche. Over the past 18 months, the REIT has lifted revenue from $681.09 million in Q4 2024 to $771.58 million in Q2 2026, a 13.5 % rise that reflects robust lease renewal momentum in outpatient and lab assets. Earnings per share swung from a $0.18 loss in Q3 2025 to $0.47 in Q4 2025 and $0.46 in Q2 2026, underscoring a return to profitability after an anomalous quarter. With a forward P/E of 62.2 and a consensus target of $22.55, the stock trades near the upper end of the peer group average of 30.1, yet its 23.2 % year‑to‑date gain suggests a market‑adjusted upside if the REIT sustains its rental income trajectory. Key risks include tightening rates that could erode net operating income and a potential slowdown in the lab portfolio. Overall, DOC offers a durable moat but investors should weigh the high valuation against the sector’s sensitivity to interest‑rate cycles.
What drives Healthpeak Properties, Inc. (DOC) stock price?
The primary catalysts for Healthpeak Properties, Inc. (DOC) revolve around its leasing pipeline and the performance of its lab and senior‑care assets. In Q2 2026, the REIT reported adjusted funds from operations of $325.4 million, or $0.46 per share, and lifted its full‑year FFO guidance to $1.73–$1.77 per share, signaling confidence in ongoing lease renewals. The company’s 6‑month return of 24.9 % reflects the market’s reaction to that guidance hike, while the 3‑month gain of 10.3 % underscores momentum from recent earnings. Additionally, the 13.5 % revenue growth from $681.09 million in Q4 2024 to $771.58 million in Q2 2026 highlights a strengthening asset base. These factors, combined with a 22.55 analyst target, form the core of DOC’s price narrative.
Does Healthpeak Properties, Inc. (DOC) pay a dividend?
Healthpeak Properties, Inc. (DOC) does not currently issue a regular cash dividend, a common practice among REITs that prefer to distribute earnings through adjusted funds from operations. Instead, the company focuses on maximizing shareholder value by reinvesting in high‑quality healthcare facilities and maintaining a disciplined capital allocation strategy. In Q2 2026, DOC generated $325.4 million in adjusted FFO, translating to $0.46 per share, which supports its ability to return capital through share buybacks or future dividend decisions. The REIT’s 22.55 consensus price target reflects expectations of continued FFO growth rather than dividend payouts. Investors seeking income should monitor any future announcements regarding a dividend policy shift. Until such a change is announced, DOC’s value proposition remains rooted in its real‑estate cash‑flow generation.
What is the valuation of Healthpeak Properties, Inc. (DOC) and how should I think about it?
When evaluating Healthpeak Properties, Inc. (DOC), the forward P/E of 62.2 places it above the peer average of 30.1, reflecting the market’s premium for its specialized healthcare portfolio. The stock sits 23.1 % above its 52‑week low of $15.70 and 15.8 % below its 52‑week high of $22.95, indicating a moderate upside potential within a defined range. With a 23.2 % year‑to‑date return, DOC has outperformed many peers, yet its 81 sentiment score and stable trend suggest cautious optimism. The consensus analyst target of $22.55 sits roughly 4 % below the current price of $21.50, implying a modest upside if the REIT continues to meet its FFO guidance. Investors should weigh the high valuation against the durability of the company’s revenue growth and its ability to sustain rental income amid rising rates. Ultimately, DOC’s valuation is justified by its niche market position but carries a premium that requires confidence in its long‑term cash‑flow resilience.
What are the risks of buying Healthpeak Properties, Inc. (DOC) stock?
Risk factors for Healthpeak Properties, Inc. (DOC) include the sensitivity of its rental income to the prevailing interest‑rate environment; a tightening cycle could elevate interest expense and compress net operating income. The REIT’s laboratory segment, which has faced recent scrutiny, may experience slower growth or require divestitures, potentially impacting future cash flows. Regulatory changes in healthcare reimbursement or zoning could also affect property valuations. Market volatility is evident in the 6‑month return of 24.9 % and the 3‑month gain of 10.3 %, indicating that DOC’s share price can swing significantly in response to earnings releases. Additionally, the high forward P/E of 62.2 suggests that the market has priced in strong growth expectations that may not materialize if economic conditions deteriorate. Investors should assess these risks in the context of their own risk tolerance and investment horizon.
How does Healthpeak Properties, Inc. (DOC) compete in the healthcare REIT market?
Healthpeak Properties, Inc. (DOC) maintains a competitive edge by owning 703 high‑quality healthcare facilities that span outpatient medical, laboratory, and senior‑care retirement communities. The REIT’s focus on long‑term, triple‑net leases generates stable cash flow and high tenant retention, creating substantial switching costs for potential competitors. Pricing power is reinforced by the specialized nature of its assets, allowing DOC to command premium rents in a sector that values proximity to medical services. Geographic diversification across the United States mitigates concentration risk, while its joint‑venture interests further broaden its market reach. The company’s disciplined capital allocation strategy, evidenced by the 22.55 analyst target and consistent FFO growth, strengthens its moat against larger, more diversified REITs. In sum, DOC’s niche positioning and asset quality underpin its ability to outperform peers in the healthcare real‑estate space.
What are the recent earnings results for Healthpeak Properties, Inc. (DOC) in Q2 2026?
In Q2 2026, Healthpeak Properties, Inc. (DOC) posted earnings per share of $0.46, a robust beat against the $0.0328 consensus estimate, and revenue of $772.0 million, surpassing the $727.0 million forecast. This performance follows a strong Q4 2025 quarter where EPS rose from a $0.18 loss to $0.47 and revenue climbed to $719.4 million. The REIT’s adjusted funds from operations of $325.4 million, or $0.46 per share, underscored its ability to generate cash flow from its portfolio. The results also led to an upward revision of the full‑year FFO guidance to $1.73–$1.77 per share. Analysts noted that the company’s leasing momentum, particularly in its lab and senior‑care segments, contributed to the earnings beat. Overall, the quarter reflects a recovery from the anomalous Q3 2025 loss and a return to consistent profitability.
How has Healthpeak Properties, Inc. (DOC) performed over the past year?
Over the past year, Healthpeak Properties, Inc. (DOC) has delivered a 23.2 % return, outperforming many peers in the real‑estate sector. The 6‑month gain of 24.9 % reflects the market’s positive reaction to the company’s recent earnings beat and FFO guidance upgrade. A 3‑month increase of 10.3 % indicates continued momentum, though the 1‑month decline of 0.3 % suggests short‑term volatility around earnings releases. The stock’s price has moved from a 52‑week low of $15.70 to a current level of $21.50, representing a 23.1 % climb above the low and a 15.8 % drop from the high of $22.95. This trajectory highlights the REIT’s resilience amid a tightening rate environment. Investors observing DOC should consider the sustained upward trend against the backdrop of its high valuation and sector‑specific risks.
What is the analyst consensus on Healthpeak Properties, Inc. (DOC) price target?
Analysts currently agree on a consensus price target of $22.55 for Healthpeak Properties, Inc. (DOC), with a range spanning $17.00 to $29.00. The majority of 26 analysts hold a buy rating, while 16 maintain a hold stance and none issue a sell recommendation, reflecting a broadly positive outlook. The target sits just below the stock’s current price of $21.50, suggesting a modest upside if the REIT continues to meet its FFO guidance. The high end of $29.00 represents a scenario where the company sustains its aggressive leasing momentum and achieves higher-than‑expected rent growth. Conversely, the low end of $17.00 accounts for potential rate‑related headwinds that could compress net operating income. Overall, the consensus signals confidence in DOC’s durable moat but also acknowledges the premium priced into its valuation.
How has Healthpeak Properties, Inc. (DOC) revenue trended over the last 18 months?
Healthpeak Properties, Inc. (DOC) has shown a steady upward trajectory in revenue over the past 18 months, climbing from $681.09 million in Q4 2024 to $771.58 million in Q2 2026. This 13.5 % year‑over‑year increase reflects the REIT’s successful lease renewals and expansion in its laboratory and senior‑care segments. The growth has been driven largely by higher occupancy rates and incremental rent increases, both of which are supported by the company’s strong tenant mix. Despite a temporary dip in Q3 2025, the subsequent quarters have rebounded, underscoring the resilience of DOC’s revenue base. The consistent revenue expansion aligns with the company’s strategy to acquire and develop high‑quality healthcare properties. As a result, DOC’s top‑line momentum is a key factor in its valuation and investor appeal.
What is Healthpeak Properties, Inc. (DOC) capital allocation policy?
Healthpeak Properties, Inc. (DOC) prioritizes capital allocation by focusing on maximizing funds from operations rather than distributing cash dividends. The REIT recently raised its full‑year adjusted FFO guidance to a range of $1.73–$1.77 per share, reflecting confidence in its lease portfolio and anticipated rent growth. While DOC does not issue a dividend, it has historically returned capital through share buybacks, a strategy that aligns with its objective of enhancing shareholder value. The company’s disciplined approach to debt management, maintaining a moderate leverage profile, also supports its ability to fund future acquisitions and refinance existing obligations. By reinvesting excess cash flow into high‑quality healthcare assets, DOC seeks to preserve and grow its income base. This allocation philosophy is consistent with the REIT’s long‑term focus on sustaining stable cash‑flow generation.
How does Healthpeak Properties, Inc. (DOC) manage its debt and interest expenses?
Healthpeak Properties, Inc. (DOC) manages its debt load by maintaining a conservative leverage ratio that balances growth financing with financial flexibility. The REIT’s exposure to interest expense has been a concern amid rising rates, yet its strong revenue growth of 13.5 % over 18 months provides a cushion for servicing debt. DOC’s disciplined capital allocation strategy, evidenced by the 24.9 % 6‑month return and the recent upgrade of FFO guidance, signals confidence in its ability to refinance at favorable terms. The company also pursues a mix of long‑term and short‑term debt to align maturities with asset cash flows, thereby reducing refinancing risk. While the current rate environment may increase borrowing costs, DOC’s portfolio quality and tenant stability help mitigate potential impacts on net operating income. Investors should monitor the REIT’s debt‑to‑EBITDA ratio and any changes in credit spreads as part of its risk assessment.
Learn More
What Is EMA and How to Read It Learn how the Exponential Moving Average helps you identify trend direction, momentum shifts, and dynamic support or resistance.
What Are Bollinger Bands and How to Read Them Learn how Bollinger Bands measure volatility, identify breakouts, and highlight overextended price conditions.
How to Use DailyIQ Email Alerts to Time Your Buys and Sells A practical walkthrough of what's inside a DailyIQ email alert and how to use the target price and upside percentage to time entries, exits, and rotations.
Breakouts, Stops & Retracements: The Institutional Trading Framework Master breakout confirmation, volume analysis, volatility filters, ATR methods, pivot techniques, anticipation signals, and professional stop-loss management.
What Is RSI and How to Read It Learn how the Relative Strength Index helps you measure momentum and identify overbought or oversold conditions.
Dow Theory History, Theorems, Trends, Confirmation, Volume & Criticisms A comprehensive and original deep dive into Dow Theory, including its historical roots, core theorems, trend classifications, confirmation principles, volume interpretation, criticisms, and modern relevance.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).